Clinical trials: DENGUE
Dengue Fever
Bridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital
Study 1: Cost-effectiveness of TAK-003 Dengue Vaccination in Thailand This study aims to evaluate the cost-effectiveness of introducing the live-attenuated tetravalent dengue vaccine (TAK-003) into Thailand's national…
- Trial name
- NCT07759596
- Testing
- Objective 1- economic evaluation of Thai children with dengue vaccine
- Where
- Thailand
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Dengue, Dengue Hemorrhagic Fever
Gut Leakage' in Dengue
Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the…
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Intestinal Disease, Ascites
- Trial name
- GLiD (NCT07602920)
- Where
- Bangladesh
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Dengue Fever
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315…
- Trial name
- NCT03999996
- Testing
- Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
- Where
- 10 sites in United States, Mexico
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in…
- Trial name
- ZAP-DENGUE (NCT04597437)
- Testing
- Zanamivir
- Where
- 2 sites in Colombia
- Volunteers
- 74 people
- Sponsor
- George Washington University
Dengue Fever With Warning Signs
Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)
This randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs.
- Trial name
- DEN-06-IB (NCT07712926)
- Testing
- Butantan-DV (IB), Butantan-DV (WuXi)
- Volunteers
- 1,765 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue Fever
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT07047521
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Australia
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue…
- Trial name
- DEN-04-IB (NCT06891950)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 5 sites in Brazil
- Volunteers
- 997 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Infectious Disease, Cardiovascular Diseases
Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France).
- Conditions
- Infectious Disease, Cardiovascular Diseases, General Population, Metabolic Disease
- Trial name
- NCT05400824
- Testing
- Blood, DNA, feces, urine, hair and skin microbiota collection
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Dengue
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
- Trial name
- NCT07576868
- Testing
- CP-COV03
- Where
- 2 sites in Vietnam
- Volunteers
- 210 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
Dengue Fever
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06665035
- Testing
- TDV
- Where
- 4 sites in Colombia, Thailand
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Takeda
Severe Dengue
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)
The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.
- Trial name
- NCT05631405
- Testing
- Dexamethasone
- Where
- 2 sites in Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Response To Dengue Exposure
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine
Background: Dengue is a disease caused by a virus transmitted by mosquitoes in tropical and subtropical regions. Dengue is a leading cause of hospital stays and death in parts of Asia and Latin America, and outbreaks have…
- Trial name
- NCT05691530
- Testing
- rDEN3Δ30/31-7164
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Dengue
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial
This will be a placebo-controlled, multicenter-randomized prospective study of CPLE (Carica papaya leaf extract) tabs in dengue patients (WHO-Group A, B).
- Trial name
- NCT06121934
- Testing
- Carica Papaya Leaf Extract
- Where
- Bangladesh
- Volunteers
- 250 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Dengue Fever
Abdominal Sonographic Findings and Their Association With Thrombocytopenia in Dengue Fever: A Cross-Sectional Study From an Endemic Region
Dengue fever is a common mosquito-borne viral infection in many tropical regions, including Sudan. Some patients develop severe forms of the disease, such as dengue hemorrhagic fever, which can lead to plasma leakage, bleeding…
- Trial name
- NCT07621848
- Where
- Sudan
- Volunteers
- 150 people
- Sponsor
- National Center for Gastroentestinal and Liver Disease
Dengue, Chikungunya
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients
Introduction: Dengue and Chikungunya arboviral diseases are considered major public health challenges in tropical regions due to high infection rates and the occurrence of musculoskeletal sequelae that impair strength, balance…
- Trial name
- NCT07600879
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Universidade do Estado do Pará
Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination.
- Trial name
- PRIME-Q (NCT06388785)
- Testing
- No Intervention
- Where
- 2 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
IC14 in Adult Patients With Dengue Fever
Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever > 38°C for < 48 hours with a positive NS1 strip…
- Trial name
- NCT03875560
- Testing
- IC14
- Sponsor
- Implicit Bioscience
Dengue, Arbovirus Infections
Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility
In contrast to the trend expected based on existing prediction models, dengue incidence was historically low during the pandemic mobility restrictions of 2020-2021 in most dengue endemic countries.
- Conditions
- Dengue, Arbovirus Infections, Epidemic Disease, Behavior, Health
- Trial name
- DI-MOB (NCT06599970)
- Testing
- No intervention
- Where
- Cuba
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Dengue, Severe Dengue
Therapeutics for Moderate and Severe Dengue
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection.
- Conditions
- Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases
- Trial name
- DEN-HOST (NCT07543458)
- Testing
- Dexamethasone, N-Acetylcysteine, Standard of care
- Where
- 18 sites in Bangladesh, Brazil and 8 more
- Volunteers
- 8,800 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam